Consumers aren’t flocking to send their spit into genetic testing companies in as high a numbers as the industry expected, an issue the industry has sounded the alarm on for the past six months.
Industry experts aren’t expecting that market to ever come back, forcing the companies to adopt new strategies. Here’s where the companies are betting the industry could go from here.I spoke with a group of biotech executives onstage Monday about what it takes to prove a new drug should be covered by insurers. TheyAndrew tuned into a discussion about biotech dealmaking.
The top dealmakers, from Centerview, JPMorgan and Raymond James, revealed the 4 areas of biotech that are ripe for takeovers in 2020, from drugs that harness the body’s immune system to more precise ways to take on cancer.a top investor at Pfizer’s $1 billion VC arm. She spoke about the 2 biggest mistakes startup biotechs make when trying to win her cash.
Some general observations: nobody’s cleared 100,000 members in Medicare Advantage yet, and I’ll be curious how long it takes for the startups to get there. Compared to the millions of members insurers like UnitedHealthcare and Humana have, the startups still have a lot of room to grow.We’ve gotten updates as well on the virus’s impact on healthcare workers in Wuhan.
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »